Market Intelligence for Myeloproliferative Neoplasm (MPN) Therapeutics and Immunogenic Cell Death Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CALR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | CALR Wild-Type Recombinant Protein ER-resident chaperone domain, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CALR Products |
| Antigen (Mutant) | CALR del52 / ins5 Mutant Proteins Type 1/2 MPN mutations with novel C-terminus, Sequence Verified, Theoretical MW confirmed. |
View CALR Products |
| Gene Delivery | CALR ORF Lentivirus (WT & Mutant) Full-length ORF with native ER signal peptide for stable cell line construction. |
View CALR Products |
| Benchmark Ab | Anti-CALR Reference Antibody Recombinant rabbit monoclonal for Western/IP validation. |
View CALR Products |
| Validator | CALR siRNA Set For knockdown verification and specificity controls. |
View CALR Products |
| Related Target: MPL | MPL (Thrombopoietin Receptor) Direct binding partner of mutant CALR; essential for oncogenic signaling. |
View MPL Products |
| Related Target: JAK2 | JAK2 (Janus Kinase 2) Downstream effector of CALR-MPL complex; resistance pathway analysis. |
View JAK2 Products |
| Related Target: PDIA3 | PDIA3 (ERp57) ER chaperone partner; CALR folding complex component. |
View PDIA3 Products |
| Related Target: CD47 | CD47 (Integrin-Associated Protein) Synergistic macrophage checkpoint ("Don't eat me" signal); regulates phagocytosis with CALR. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Screening | Strictly purified CALR-del52 and CALR-ins5 Mutant Proteins with MS-verified novel C-terminus; Wild-type protein controls available from same production batch. |
| CALR-MPL Binding Inhibition | High-purity CALR variants (Human/Mouse) and MPL ECD-Fc proteins for SPR/BLI heterodimer assays. |
| Intracellular vs Surface Detection | Lentiviral expression systems (HEK293 derived) for stable cell line generation; preserve native glycosylation and conformation. |
| Cross-species Preclinical Translation | Human/Mouse/Rat CALR ortholog proteins available with >95% purity for comparative pharmacology. |
| False Positives in Binding Assays | Validated CALR siRNA included for specificity checks and target engagement verification. |
Live CALR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CALR therapeutics is intensifying, with major players shifting focus from generic JAK inhibitors to mutant-specific CALR-MPL disruptors and mutant-specific monoclonal antibodies. As first-generation JAK inhibitors (ruxolitinib, fedratinib) provide symptomatic relief but fail to address the driver mutation, the next wave of R&D is targeting the CALR-MPL protein-protein interaction (PPI) , mutant-specific neoantigens for vaccine development, and the intersection of CALR as an "eat me" signal with immune checkpoint modulation.
In the immuno-oncology space, surface-exposed CALR (ecto-CALR) serves as the primary "eat me" signal for immunogenic cell death (ICD). Drug development here focuses on CALR exposure inducers, anti-CALR antibody-drug conjugates, and bispecific modalities (e.g., CALR × CD47) to enhance tumor immunogenicity and overcome CD47-mediated immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Preclinical Biotechs, NCGC | CALR+ Myelofibrosis (PMF), Essential Thrombocythemia (ET) | Mutant vs WT Selectivity (Need CALR-del52/ins5 vs WT proteins) |
| Mutant-Specific mAb | MorphoSys, Incyte | Myeloproliferative Neoplasms (MPN) | Selectivity Assay (Need Mutant vs WT Proteins) |
| Peptide Inhibitor | Academic Institutions | CALR+ MPNs | Competitive Binding Assay (Need purified CALR mutant C-terminus) |
| Mutant-Specific Vaccine | Immuno-oncology startups, Academic/Biopharma | CALR+ MPNs, Essential Thrombocythemia | Neo-epitope Validation (Need mutant-specific antibodies) |
| Bispecific (CALR × CD47) | Various Biotechs | Solid Tumors / AML | Heterodimer Validation (Need cross-reactive Abs and dual-antigen binding assays) |
| ADC / mAb (Anti-ecto-CALR) | Oncology-focused Pharma | Solid Tumors (ICD enhancement) | Cell Surface Binding (Need CALR+ stable cell lines via Lentivirus) |